Arkolith/Insider Trading/KALV/Form 4

Palleiko Benjamin L

CHIEF EXECUTIVE OFFICER, DirectorKalVista Pharmaceuticals, Inc. (KALV) · full profile →Form 4 · filed May 19, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$30K
Net Open-Market Flow
-$30K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 18, 2026Sell(S)1K$26.76$30K468K
May 17, 2026Option exercise(M)2K——469K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 17, 2026Option exercise(M)2K—$00

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001366244-26-000009) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML